7th Annual Pulmonary Embolism Symposium (2021)

October 15, 2021 to October 16, 2021



The PERT Consortium was formed to promote best practices in Pulmonary Embolism (PE) care. By focusing solely on the entirety of PE – its etiology, pathophysiology, prevention, management approach, outcomes of specific treatments, and follow-up pathways – it is the intention of the Consortium to increase awareness of treatment options available to patients with PE, to reduce its incidence worldwide, to improve health outcomes, and to positively influence the impact of this terrible disease.

This annual 2 day, AMA PRA/ANCC‐accredited conference entitled, ”Pulmonary Embolism: What is Known, and What We Need to Know: A State of the Art and Scientific Update”, is designed for practicing clinicians who regularly care for patients with acute and chronic pulmonary embolism (PE), as well as those who are interested in studying the pathophysiology, epidemiology, diagnosis, prevention, medical and interventional management, novel treatment paradigms, and outcomes of pulmonary embolism (PE).  The meeting agenda has been expanded to include topics and presentations surrounding COVID-19 and the unique association of this virus with Venous Thromboembolic Disease (VTE), and specifically its impact on incidence, diagnosis and unique management strategies of Pulmonary Embolism.

The annual PERT business meeting will take place on October 14th.

This meeting will be all virtual (as of 8/25).  If you have registered to attend in person, we will be contacting you to change your registration.

Learn more about the PERT Consortium at https://pertconsortium.org or the conference website here.

This program is supported by educational grants from:

  • Boston Scientific
  • Cook Medical
  • Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC
  • Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance
  • Abiomed

Target Audience

This two day course is designed to educate practicing clinicians who diagnose and/or treat patients with pulmonary embolism; academics and scientists who study pulmonary embolism.

Learning Objectives

At the conclusion of this activity, the participants will be able to:

  • Discuss the epidemiology and pathophysiology of PE, including how to assess the risk of patients presenting with symptoms consistent with PE.
  • Identify features that define low, intermediate and high‐risk PE
  • Develop a diagnostic and treatment algorithm that incorporates risk stratification and meets the specific needs of patients presenting with signs and symptoms of PE.
  • Appropriately select among various treatment options for intermediate‐ and high‐risk PE patients including: anticoagulation, fibrinolysis (intravenous and catheter‐directed), extra‐corporeal membrane oxygenation (ECMO), thrombectomy (suction and surgical), and IVC filter placement.
  • Recognize the potential acute complications of PE and how to prevent and treat them.
  • Develop algorithm to identify and manage long term consequences of PE, such as CTEPH and CTED; understand combination of pharmacologic and mechanical treatment options available for use in such patients.
  • Describe unique patient populations with PE and their specific treatment challenges
  • Discuss the benefits of a multidisciplinary approach to PE management, and how to implement a PE Response Team (PERT) in their hospital.
  • Identify what constitutes high quality care for PE.
  • Target opportunities for quality improvement at an institutional level.
  • Address thrombosis issues related to COVID-19, specifically:
  • Delineate the risk of thrombosis associated with COVID-19 infection
  • Characterize the various manifestations and presentations of thrombosis and VTE seen with COVID-19, including the VITT syndrome
  • Identify the proper testing pathways for COVID-19 associated clotting disorders
  • Specify anticoagulation regimens currently utilized to treat active thrombosis, as well as the range of therapeutics available as prophylaxis to prevent recurrence in hospitalized patients.
  • Delineate proper anticoagulation strategies for hospitalized COVID-19 patients
  • Define proper anticoagulation for outpatients with active or convalescent infection
  • Prescribe appropriate treatment/prophylaxis after discharge of COVID-19 patients
  • Define the value and benefits of the multi-disciplinary approach in the management of PE and VTE, including the PERT approach
  • Establish the role of PERT in COVID-19 patient, including adjustments in the treatment paradigms necessitated by active infection
Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Live activity for a maximum of 14.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 14.25 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
    • 8.00 ANCC Pharmacology
  • 14.00 Participation
Course opens: 
07/01/2021
Course expires: 
10/16/2022
Event starts: 
10/15/2021 - 7:00am
Event ends: 
10/16/2021 - 5:20pm
Cost:
$149.00

Please click here for the full Symposia program on October 15-16, 2021.  THe Annual Business Meeting agenda on 10/14/21 is below.

 

Annual Business Meeting
October 14, 2021
7:00 – 8:00 PM

 

7:00 – 7:10 PM

 

Welcome & State of the Consortium

Rob Lookstein, MD

7:10 – 7:15 PM

Finance Update

Tom Todoran, MD

 

7:15 – 7:20 PM

Announcement of New Slate

Roy Smith, MD

 

7:20 – 7:25 PM

Voting on New Slate

 

 

7:25 – 7:55 PM

Committee Updates
  Communications

  Clinical Protocols

  Database

  Development
  Education
  Finance

  Governance

  Research

Rachel Rosovsky, MD

Brandon Hooks, DO

Parth Rali, MD

Rob Lookstein, MD

Ken Rosenfield, MD

Bushra Mina, MD

Matt Langston, MD

Seth Sokol, MD

Eric Secemsky, MD

 

7:55 – 8:00 PM

Future of the Consortium

Brent Keeling, MD

 

Industry Meeting

October 14, 2021

8:15 – 9:15 PM

 

8:15 – 8:20 PM

Welcome & Introductions

Board of Directors & Committee Chairs

 

Roy Smith, MD        

 

8:20 – 8:30 PM

State of the Consortium – View from the President

  Overview of 2020-21: Progress, Accomplishments   

  and Highlights

 

Rob Lookstein, MD

 

8:30 – 8:35 PM

PERT Database Version 2.0

  Vision and Goals

 

Eric Secemsky, MD

 

8:35 – 8:50 PM

Corporate Community

  Database Liaison Committee

  Value Proposition

  FDA Collaboration

 

Brent Keeling, MD

Rob Lookstein, MD

Ken Rosenfield, MD

Rachel Rosovsky, MD

8:50 – 8:55 PM

Future of the Consortium

 

Brent Keeling, MD

8:55 – 9:15 PM

Open Discussion and Q&A

Brent Keeling

 

 

 

Course Co-Directors

Emilly Gundert, MD FAAEM

https://www.bucme.org/uploads/faculty/26023-281752985.jpg  Assistant Professor of Emergency Medicine
  Assistant Professor of Anesthesia/Pain Management, Division of Critical Care
  UT Southwestern

 

Menno Huisman, MD, PhD, FESC

https://www.bucme.org/uploads/faculty/17593-202543820.jpg  Professor of Medicine.
  Internist in Cardiovascular Medicine
  Professor of Medicine
  Department of Thrombosis and Hemostasis
  Leiden University Medical Center, Leiden, the Netherlands

Scott Kaatz, DO, MSc, FACP, SFHM

https://www.bucme.org/uploads/faculty/11277-683774873.jpg  Senior Staff Hospitalist
  Medical Director for Professional Development and Research
  Division of Hospital Medicine
  Henry Ford Hospital

 

John Moriarty, MD FSIR

https://www.bucme.org/uploads/faculty/17889-1047137898.jpg  Program Director
  Interventional Radiology
  UCLA Medical Center
  Los Angeles, CA

 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and PERT Consortium. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 14 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity has been provided by  Boston University School of Medicine Continuing Nursing Education and jointly-provided by PERT Consortium.

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Available Credit

  • 14.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Live activity for a maximum of 14.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 14.25 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
    • 8.00 ANCC Pharmacology
  • 14.00 Participation

This program is supported by educational grants from:

  • Abiomed

  • Boston Scientific

  • Cook Medical

  • Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

  • Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance

 

This program is supported by exhibit fees from:

 

Platinum

  • AIDOC
  • Angiodynamics
  • Boston Scientific
  • Inari
  • Janssen
  • Penumbra

Gold

  • Bristol Myers Squibb and Pfizer Alliance
  • RapidAI

Silver

  • BD
  • Bayer
  • Cook Medical
  • Viz.ai

Price

Cost:
$149.00
Please login or register to take this course.
Pricing

Physicians 

$149

Advance Practice Provider  (Pharmacist, NP, RN etc.)  

$99

Trainee

$0

Industry 

$549

 

To pay by check, please create an account and email us at cme@bu.edu or call 617-358-5005 and we will assist you.
Cancellation Policy

Substitutions may be made at any time without an additional charge. Refunds, less an $50 administrative fee, will be issued for all cancellations received two weeks prior to the start of the meeting. Should cancellation occur within the two-week window, a credit will be issued, not a refund. Credits will be honored for up to two years. “No shows” are subject to the full course fee. Cancellations/substitution(s) must be made in writing. Refunds or credits will not be issued once the conference has started. This course is subject to change or cancellation.

Special Services / Dietary Needs

To request reasonable accommodations for disabilities, please notify the Office of Continuing Medical Education in writing at least two weeks prior to the start of the conference. The Office of Continuing Medical Education will work to accommodate dietary requests (including, but not limited to: kosher, vegetarian, low cholesterol, and low sodium) received in writing at least two weeks prior to the start of the conference

Please Note

The conference organizers may take pictures or record videos during the conference. In registering for the conference, you acknowledge that BUSM may photograph you during the meeting, and you agree that we may include images of yourself, intact or in part, for conference promotional activities or other related endeavors. This material may also appear on the conference's website or associated social media outlets. If you do not wish to be photographed, please let the BUSM representative onsite know